AbCellera Biologics has priced its oversubscribed underwritten public offering of 17.44 million common shares at $9.75 per share. The company is also offering pre-funded warrants to purchase up to 3.08 million common shares at $9.74999 per warrant, representing the public offering price minus a $0.00001 exercise price. Gross proceeds from the offering are expected to be approximately $200.0 million, with all securities sold directly by AbCellera and closing expected on August 14, 2026. The company plans to use the net proceeds to fund research, development, and clinical advancement of its internal pipeline, including its lead clinical program ABCL635, as well as for working capital and general corporate purposes. Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets are acting as joint book-running managers for the transaction.
Abcellera Biologics IncPriced $200M offering at $9.75, diluting existing shareholders.
JPMorgan Chase & Co
